SNMMI In The News

May 9, 2012

Amyloid Imaging: The Next Frontier in Alzheimer’s Care

Diagnostic Imaging

With the FDA approval last month of the radioactive diagnostic agent florbetapir, the industry continued the trend toward improved identification of beta-amyloid, the brain plaque associated with Alzheimer’s disease. Questions still exist about how best to use these tracers, but industry experts view these developments as significant positives for patient care.

Related Items